Foresite Capital Management IV, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Foresite Capital Management IV, LLC reported 7 stock positions worth $229.7 million. Its top holding was Pharvaris (PHVS) at 57.7% of the portfolio, followed by Cytokinetics (CYTK, 12.7%) and Lyell Immunopharma (LYEL, 10.7%). Compared with Q3 2025, it opened 1 new position. The biggest buy was a new position in Alector (ALEC).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0001704132
- Portfolio Value
- $229.7M (Q4 2025)
- SEC Filing
- 0001104659-26-015407 ↗ filed Feb 17, 2026
Holdings Value
Holdings 7 stocks · $229.7M
| PHVS Pharvaris NV | 57.73% | 4,778,581 | $132.6M | No change |
| CYTK Cytokinetics Inc. | 12.68% | 458,295 | $29.1M | No change |
| LYEL Lyell Immunopharma Inc. | 10.72% | 800,399 | $24.6M | No change |
| MAZE Maze Therapeutics Inc. | 9.43% | 522,657 | $21.7M | No change |
| RLAY Relay Therapeutics Inc. | 3.68% | 1,000,000 | $8.5M | No change |
| XENE Xenon Pharmaceuticals Inc. | 3.12% | 160,000 | $7.2M | No change |
| ALEC Alector Inc. | 2.64% | 3,887,200 | $6.1M | New |
Portfolio Sells Q3 2025 → Q4 2025
| None this quarter. | |||
Portfolio Buys Q3 2025 → Q4 2025
| ALEC Alector Inc. | New | 2.64% | +2.64 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $290.2M | PHVS, CYTK, EIKN, RLAY, XENE |
| Q1 2026 | 8 | $237.1M | PHVS, CYTK, EIKN, LYEL, RLAY |
| Q4 2025 | 7 | $229.7M | PHVS, CYTK, LYEL, MAZE, RLAY |
| Q3 2025 | 6 | $182.6M | PHVS, CYTK, MAZE, LYEL, XENE |
| Q2 2025 | 6 | $123.8M | PHVS, MAZE, LYEL, XENE, KURA |
| Q1 2025 | 5 | $111.1M | PHVS, MAZE, LYEL, KURA, RLAY |
| Q4 2024 | 4 | $108.8M | PHVS, KURA, LYEL, RLAY |
| Q3 2024 | 5 | $153.0M | PHVS, KURA, SNDX, LYEL, RLAY |
| Q2 2024 | 4 | $148.8M | PHVS, KURA, SNDX, LYEL |
| Q1 2024 | 5 | $197.9M | PHVS, KURA, KNTE, SNDX, LYEL |